Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands

Intravenous targeting of anticancer agents should improve both efficacy and therapeutic index. However, rational design of targeting constructs requires detailed definition of receptor targets and must take account of polarised tissue architecture that may restrict access to chosen receptors from the bloodstream. Bacteriophage biopanning provides a solution to this problem, identifying targeting sequences by functional selection rather than design, although reiterative panning in polarized human tumours has not previously been attempted. Here, we report an ex vivo, intra-arterial method for biopanning in freshly-resected human tumours, enabling reiterative selection of oligopeptide sequences capable of intravascular targeting to human colorectal tumours. Significant consensus was observed after two rounds of panning in tumours from different patients, and lead sequences demonstrated tumour targeting in samples from unrelated patients. This novel approach may be applicable to a wide range of settings, thus enabling iteration of consensus targeting sequences for tumour imaging and selective delivery of anticancer agents.

[1]  D. Krag,et al.  Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library. , 2005, Oncology reports.

[2]  B. Pützer,et al.  Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma , 2005, The journal of gene medicine.

[3]  D. Krag,et al.  Phage display selection for cell-specific ligands: Development of a screening procedure suitable for small tumor specimens , 2005, Journal of drug targeting.

[4]  P. Lam,et al.  Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. , 2004, Human gene therapy.

[5]  Linda A Landon,et al.  Combinatorial discovery of tumor targeting peptides using phage display , 2003, Journal of cellular biochemistry.

[6]  Kim-Anh Do,et al.  Steps toward mapping the human vasculature by phage display , 2002, Nature Medicine.

[7]  Alan L Parker,et al.  Identification of FGF receptor-binding peptides for cancer gene therapy , 2002, Cancer Gene Therapy.

[8]  Erkki Ruoslahti,et al.  Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Curiel,et al.  Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. , 2002, Cancer research.

[10]  M. Backer,et al.  Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. , 2001, Bioconjugate chemistry.

[11]  R Pasqualini,et al.  Molecular addresses in blood vessels as targets for therapy. , 2001, Current opinion in chemical biology.

[12]  K. Ulbrich,et al.  Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies , 2001, Gene Therapy.

[13]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.

[14]  Erkki Ruoslahti,et al.  Membrane Dipeptidase Is the Receptor for a Lung-targeting Peptide Identified by in Vivo Phage Display* , 1999, The Journal of Biological Chemistry.

[15]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[16]  V. Combaret,et al.  In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer , 1997, Gene Therapy.

[17]  I. Pastan,et al.  Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[19]  U. Haberkorn,et al.  A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.